DCM
BIIB icon

Defilade Capital Management’s Biogen BIIB Stock Holding History

Defilade Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-96,289
Closed -$17.7M – 43
2026
Q1 		$17.7M Sell
96,289
-65,703
-41% -$12.1M 2.48% 20
2025
Q4 		$28.5M Buy
+161,992
New +$26.5M 3.86% 10

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Defilade Capital Management's BIIB Position: Q2 2026 in Review

Defilade Capital Management sold out of Biogen (BIIB) in Q2 2026, closing a stake of 96,289 shares — an estimated $17.7M sold.

Defilade Capital Management first reported a position in BIIB in Q4 2025 and held it in 2 quarters. The position peaked at $28.5M in Q4 2025. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Defilade Capital Management reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
  • Defilade Capital Management sold 96,289 Biogen shares in Q2 2026, an estimated $17.7M.
  • Defilade Capital Management first reported a position in Biogen in Q4 2025 and held it in 2 quarters.
  • Defilade Capital Management's Biogen position peaked at $28.5M in Q4 2025.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Defilade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.